HIGHLIGHTS
- who: Xinpeng Wang from the Fujian Medical University, China have published the research work: Real-world experience with antiu2013programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study, in the Journal: (JOURNAL) of 30/Dec/2021
- what: The studies on ATTRCTION-3 , ESCORT , and KEYNOTE-181 have shown that immunotherapy, as a treatment for advanced second-line EPC, has significantly better Objective Response Rate (ORR) and Overall Survival rate (OS) than the chemotherapy control group and has good safety. The authors also evaluated the safety of immunotherapy for EPC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.